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Curcumin blocks multiple sites of the TGF-b signaling cascade
in renal cells
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Curcumin blocks multiple sites of the TGF-b signaling cascade
in renal cells.
Background. Over-expression of transforming growth factor-
b (TGF-b) contributes greatly to fibrotic kidney disease. The
activator protein-1 (AP-1) inhibitor curcumin, a polyphenolic
compound derived from Curcuma longa, has been shown to re-
duce collagen accumulation in experimental pulmonary fibro-
sis. Here, we investigate curcumin’s ability to modulate TGF-b ’s
profibrotic actions in vitro.
Methods. NRK49F rat renal fibroblasts were stimulated with
TGF-b (5 ng/mL), and the effects of curcumin on TGF-b–
regulated genes, TGF-b receptors, and phosphorylated SMAD
isoforms were analyzed by Northern blotting, enzyme-linked
immunosorbent assay (ELISA), and Western blotting. The ef-
fects of c-jun depletion on TGF-b–regulated gene and protein
expression were analyzed with RNAi.
Results. When applied 30 minutes before TGF-b , curcumin
dose dependently and dramatically reduced TGF-b–induced in-
creases in plasminogen activator inhibitor-1 (PAI-1), TGF-b1,
fibronectin (FN) and collagen I (Col I) mRNA, and in PAI-1 and
fibronectin protein. Prolonged curcumin treatment (>6 h) sig-
nificantly reduced TGF-b receptor type II levels and SMAD2/3
phosphorylation in response to added TGF-b . Depletion of cel-
lular c-jun levels with a RNAi method mimicked the effects
of curcumin on expression of TGF-b1, FN, and Col I, but not
PAI-1.
Conclusion. Curcumin blocks TGF-b’s profibrotic actions
on renal fibroblasts through down-regulation of TbRII, and
through partial inhibition of c-jun activity. These in vitro data
suggest that curcumin might be an effective antifibrotic drug in
the treatment of chronic kidney disease.
The accumulation of extracellular matrix proteins is
the key feature of chronic fibrotic kidney disease. Trans-
forming growth factor-beta (TGF-b) is central to the de-
velopment of fibrosis through its stimulating effect on
matrix protein generation and its inhibitory effect on ma-
trix protein removal [1]. Expression of TGF-b is elevated
in multiple forms of experimental and human kidney dis-
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ease, ranging from diabetic nephropathy and glomeru-
lonephritis to tubulointerstitial nephritis. Experimental
therapies aimed to reduce fibrosis have been shown to re-
duce TGF-b over-expression whether they directly target
TGF-b or not. Thus, direct targeting of TGF-b may well
be a valid therapeutic approach. Based upon significant
recent progress elucidating TGF-b’s complex signaling
cascade, it now appears possible to attempt therapeutic
strategies aimed at disrupting TGF-b signaling [2, 3].
In this study we evaluated the antifibrotic effect of cur-
cumin, a natural polyphenolic compound because it had
been shown to limit the accumulation of collagen fibers
in a TGF-b–driven model of fibrotic lung disease [4]. In
addition, curcumin has been shown to be an inhibitor of
the transcription factor c-jun/activator protein-1 (AP-1)
through its ability to directly bind to c-jun and block its
interaction with its DNA binding site [5–8].
Using cultured renal fibroblasts we tested the hypoth-
esis that curcumin inhibits TGF-b–induced increases in
fibrotic matrix components. We further hypothesized that
curcumin acts by inhibiting TGF-b signaling by inhibiting
the action of c-jun.
METHODS
Reagents
Cell culture reagents, curcumin, and all other reagents
were from Sigma (St. Louis, MO, USA). TGF-b1 was
purchased from R&D Systems (Minneapolis, MN, USA).
Fetal calf serum (FCS) was from Hyclone (Logan, UT,
USA). Curcumin was dissolved in 100% ethanol as a
stock solution of 20 mmol/L, and was kept protected from
light at 20◦C.
Cell culture
Primary rat mesangial cells were derived from rat
glomeruli and used between passages 5 to 8. Rat re-
nal fibroblasts from American Type Culture Collection
(NRK49F; Manassas, VA, USA) were propagated in
complete RPMI 1640 with 10% FCS. Cells were seeded in
6-well plates, grown to confluency, and rested in medium
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Table 1. Effect of curcumin (0 to 20 lmol/L) on confluent NRK49F fibroblast (NRK) and rat mesangial cell (Mes) viability
Curcumin lmol/L 0 1 2.5 5 7.5 10 12.5 15 20
NRK 0.46 ± 0.02 0.47 ± 0.01 0.48 ± 0.01 0.53 ± 0.01 0.62 ± 0.04 0.47 ± 0.02 0.44 ± 0.15 0.2 ± 0.12 0.0 ± 0.00
Mes 0.62 ± 0.03 0.65 ± 0.02 0.60 ± 0.03 0.63 ± 0.04 0.56 ± 0.02 0.58 ± 0.02 0.59 ± 0.16 0.66 ± 0.20 0.02 ± 0.01
Cells were rested in 0% FCS medium overnight and treated with curcumin for 24 hours. Cell viability was assayed by MTT test. Data are given as mean ± SD of
three separate experiments with triplicate values for each curcumin concentration.
without FCS overnight. The next morning, cells were
treated with curcumin at the indicated doses and times,
followed by TGF-b treatment at 5 ng/mL. Preliminary ex-
periments showed that curcumin was nontoxic at doses
of 0 to 10 lmol/L, and that toxicity occurred at doses
of 20 lmol/L in NRK49F fibroblasts and rat mesangial
cells (Table 1). Initial control experiments included sol-
vent (ethanol) at doses of up to 1 lL/mL, which did not
affect TGF-b effects or cell viability (data not shown).
Cells were harvested after six hours for determination
of RNA levels, and after 24 hours for analysis of TGF-b–
regulated protein expression.
Northern blotting
After treatment, RNA was harvested with Trizol (In-
vitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. Northern blotting was performed
using Ambion’s NorthernMax Gly System (Austin, TX,
USA). Probes were labeled with P32 using the Strip-EZ
Labeling kit (Ambion), and hybridized overnight in Ul-
trahyb hybridization buffer (Ambion). After washing,
blots were exposed to films that were scanned and ana-
lyzed by densitometry. Optical density (OD) values were
standardized to 18s rRNA bands to correct for loading
variations.
Western blotting
For Western blotting, treated cells were harvested at
the indicated times by the addition of ice-cold lysis buffer
for 15 minutes. After that, an aliquot was removed for
protein determination, and the remainder of the sam-
ple was boiled at 95◦C after the addition of 4× Laemmli
buffer. Samples were run on Novex 10% SDS-PAGE gels
(Invitrogen), and transferred to Immobilon polyvinyli-
dine difluoride (PDVF) membranes. After blocking with
5% dry milk in Tris-buffered saline with 0.1% Tween
(TBST), blots were incubated with antibodies in 1%
bovine serum albumin (BSA) in TBST for 1 hour at room
temperature or overnight at 4◦C. The following anti-
bodies were used: plasminogen activator protein-1 (PAI-
1; American Diagnostica, Inc., Greenwich, CT, USA);
TbRII (C16), TbRI (R20), AT1R (N10), c-jun (D), all
from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
p-SMAD2/3 (Calbiochem, San Diego, CA, USA), beta-
actin (Sigma). All secondary antibodies were from Santa
Cruz Biotechnology. Blots were developed with chemi-
luminescence with the ECL reagent from Amersham
(Piscataway, NJ, USA).
Blots were also stained for beta-actin to control for
loading variations. For PAI-1 Western blots, aliquots from
the cell culture medium were removed from the dish, cen-
trifuged shortly, and boiled for 5 minutes after the addi-
tion of 4× Laemmli buffer. The cell layer was harvested
and analyzed for protein content.
ELISA
Fibronectin enzyme-linked immunosorbent assay
(ELISA) measurements were performed as previously
described [9].
siRNA experiments
RNA interference experiments were performed using
a 21-mer siRNA molecule that targets bp 445 to 466 of
the rat c-jun molecule (Genbank accession # X 17163,
sequence of sense strand: 5′-GAUUCUGAAGCAGAG
CAUGtt-3′, sequence of antisense strand: 3′-ttCUA
AGACUUCGUCUCGUAC-5′). Both strands were syn-
thesized at the University of Utah DNA Synthesis Core
Facility, and contain at their 3′-ends two DNA thymidines.
Annealing was performed as suggested by Elbashir et al
[10]. Before transfection, fibroblasts were rested in 1%
FCS medium overnight and then transfected with Oligo-
fectamine (Invitrogen) and siRNA according to the man-
ufacturer’s instructions, and as indicated in the figure
legends. Forty-eight hours after transfection, cells were
harvested as described above, and c-jun content was ana-
lyzed by Western blotting. To test the effects of c-jun de-
pletion on TGF-b effects, cells were treated with TGF-b
for 6 hours for RNA experiments, or 24 hours for protein
experiments as described above after c-jun depletion.
Statistical analysis
Results were analyzed for statistical significance by
t test with Bonferroni correction. A P value of < 0.05
was regarded as significant.
RESULTS
Dose-dependent curcumin effects on TGF-b–induced
expression of profibrotic genes
TGF-b treatment up-regulates mRNA expression of
several profibrotic genes in quiescent renal fibroblasts. As
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Fig. 1. Curcumin dose dependently inhibits TGF-b–induced increases
in plasminogen activator protein-1 (PAI-1), transforming growth factor-
b (TGF-b), fibronectin (FN), and collagen I (COL I) mRNA expression.
Fibroblasts were incubated with curcumin at the indicated dose for
30 minutes, followed by treatment with TGF-b for 6 hours. mRNA
expression was analyzed by Northern blotting. (A) A representative
experiment is shown. (B) The mean ± SD of values obtained from
densitometric analysis of all individual experiments is shown. ∗P < 0.01
vs. TGF-b alone.
shown in the first two lanes of Figure 1A, treatment with
5 ng/mL TGF-b for 6 hours leads to increased expres-
sion of PAI-1, TGF-b1, fibronectin (FN), and collagen I
(COL I). Pretreatment with curcumin for 30 minutes ef-
fectively blocks these TGF-b effects. While 1 lmol/L cur-
cumin failed to show an effect, doses of 7.5 to 10 lmol/L
curcumin showed maximal inhibition of TGF-b effects.
Curcumin effects on TGF-b–induced gene
expression over time
To determine whether the inhibition of TGF-b effects
by curcumin is stable over time, we incubated fibroblasts
with or without curcumin pretreatment (30 minutes) with
TGF-b for up to 24 hours. Figure 2 shows that curcumin
can block TGF-b induction of PAI-1 and FN for up to
8 hours. The effect of this short pretreatment is lost be-
tween 8 and 24 hours.
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Fig. 2. Effects of curcumin on a time course of TGF-b–stimulated
mRNA synthesis. Fibroblasts were incubated with curcumin
(10 lmol/L) for 30 minutes, followed by treatment with TGF-b for
the indicated period of time. (A) mRNA expression was analyzed
by Northern blotting. (B) The mean ± SD of values obtained from
densitometric analysis of all individual experiments is shown. ∗P <
0.01 vs. TGF-b alone.
Time-dependent curcumin effects on TGF-b: Effect of
pre- and post-treatment with curcumin relative to TGF-b
Although the inhibitory effect of curcumin on TGF-b–
mediated gene transcription could be seen after a rather
short pretreatment of 30 minutes, we wondered if cur-
cumin was also effective if applied to cells after TFGb . As
Figure 3 shows, curcumin could be applied to cells as much
as 2 hours after TGF-b and still significantly reduce TGF-
b effects on PAI-1 and FN. However, maximal inhibitory
effects were observed with curcumin pretreatment. TGF-
b–induced PAI-1 was maximally reduced when curcumin
was applied 1 hour before TGF-b , and was lost after
24 hours. FN expression remained significantly inhibited
even after 24 hours of curcumin pretreatment (Fig. 3).
Curcumin effects on TGF-b–induced protein expression
The effect of curcumin treatment on TGF-b–induced
PAI-1 and FN protein production was measured in cell
culture supernatant that was derived from cells treated
for 24 hours with TGF-b after a short (30 minutes) pre-
treatment with curcumin. As Figure 4 shows, TGF-b in-
duces a strong increase in PAI-1 (Fig. 4A and B) and FN
(Fig. 4C) released into the supernatant. These TGF-b ef-
fects are blocked dose dependently by curcumin (Fig. 4).
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Fig. 3. Effect of pre- and post-treatment with curcumin relative to
TGF-b on the inhibitory effect of curcumin. Fibroblasts were incubated
with TGF-b for 6 hours, and curcumin (10 lmol/L) was given 1 or
2 hours after TGF-b concomitantly with TGF-b , or cells were pretreated
with curcumin before TGF-b for up to 24 hours, followed by 6 hours
of TGF-b treatment. (A) mRNA expression was analyzed by Northern
blotting. (B) The mean ± SD of values obtained from densitometric
analysis of all individual experiments is shown. ∗P < 0.01 vs. TGF-b
alone.
Curcumin reduces TGF-b receptor type II
expression on renal fibroblasts
Binding of TGF-b to its type II receptor starts the in-
teraction of a complex chain of signaling molecules, and
finally leads to TGF-b–induced gene transcription. To de-
termine which part of TGF-b signaling was changed by
curcumin we investigated the expression of TGF-b recep-
tors I and II after curcumin treatment. As Figure 5 shows,
there is a dose-dependent decrease in TbRII protein ex-
pression after 8-hour treatment with curcumin. This ef-
fect is small and nonsignificant at low doses of curcumin,
but becomes large and highly significant at doses of 5 to
10 lmol/L curcumin. In addition, as shown in Figure 6,
cells must be treated for at least 6 hours with curcumin
before any down-regulation of TbRII occurs. The pro-
tein expression of the type I TGF-b receptor (TbRI)
and the unrelated angiotensin type I (AT1R) cell sur-
face receptors remain unchanged by curcumin treatment
(Fig. 6).
Prolonged curcumin treatment reduces
TGF-b–induced phosphorylation of SMAD 2/3
To show that the down-regulation of TbRII by
curcumin is of functional significance, we indirectly
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Fig. 4. Curcumin dose dependently reduces TGF-b–induced PAI-1
and FN protein production. Fibroblasts were incubated with curcumin
at the indicated dose for 30 minutes, followed by treatment with TGF-b
for 24 hours. (A) PAI-1 protein released into the cell culture supernatant
was analyzed by Western blot. (B) Results of a typical experiment. (C)
The mean ± SD of values obtained from densitometric analysis of all
individual experiments. ∗P < 0.01 vs. TGF-b alone.
measured the kinase activity of the TGF-b receptor
complex by analyzing SMAD2/3 phosphorylation after
TGF-b treatment. SMAD proteins are phosphorylated
by the activated TbR complex, and subsequently translo-
cate to the nucleus, where they act as DNA-binding
transcription factors. Treatment of quiescent cells with
5 ng/mL TGF-b profoundly increases phosphorylated
SMAD 2/3, which is detectable as early as 1 minute after
treatment, and reaches a plateau after 5 minutes of treat-
ment (Fig. 7). Pretreatment with curcumin for 8 hours
blocks SMAD phosphorylation by about 50%. Our con-
clusions, based on the data presented in Figures 5 to 7, are
that prolonged treatment with curcumin at higher doses
for several hours blocks the TGF-b signaling chain by
interfering with TbRII expression and SMAD phospho-
rylation. While this may explain the inhibitory effects of
curcumin on TGF-b–induced proteins after 24 hours of
TGF-b treatment (shown in Fig. 4), it fails to explain the
profound inhibitory effect seen after only 30 minutes of
pretreatment shown in Figures 1 to 3.
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Fig. 5. Curcumin dose dependently reduces TGF-b receptor type II
(TbRII) expression. Fibroblasts were incubated with curcumin at the
indicated dose for 8 hours. TbRII protein expression was analyzed by
Western blot along with b-actin as a loading control. (A) Results of a
typical experiment. (B) The mean ± SD of values obtained from den-
sitometric analysis of all individual experiments. ∗P < 0.01 vs. control.
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Fig. 6. Curcumin selectively reduces TbRII expression, but fails to
modulate TbRI or AT1R levels. Fibroblasts were incubated with cur-
cumin (10 lmol/L) for the indicated time, and TbRII, TbRI, and AT1R
protein were analyzed by Western blot. (A) Results of a typical ex-
periment. (B) The mean ± SD of values obtained from densitometric
analysis of all individual experiments. ∗P < 0.01 vs. control.
Effects of curcumin on mesangial cells
stimulated by TGFb
To exclude that the observed effects of curcumin are
dependent on the specific genetic background of a sin-
gle, transformed cell line, we also analyzed its effects in
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Fig. 7. Prolonged pretreatment with curcumin leads to reduced phos-
phorylation of SMAD 2/3 after TGF-b treatment. Fibroblasts were
treated with TGF-b for up to 30 minutes, which induces maximal phos-
phorylation of SMAD2/3. Pretreatment with curcumin for 8 hours leads
to reduced phosphorylation of SMADs after TGF-b treatment, as mea-
sured by Western blot (A). ∗P < 0.01 vs. TGF-b 30 minutes (B).
primary rat mesangial cells. While somewhat similar to re-
nal fibroblasts, these mesangial cells are not transformed,
and possibly represent the in vivo situation more closely
than a cell line. Figure 8 shows the effects of curcumin
treatment in mesangial cells (passage 5–8). As Figure 8A
shows, treatment of mesangial cells with curcumin blocks
the induction of PAI-1 and FN mRNA by TGFb . Sim-
ilar results were obtained with NRK52E cells, a renal
epithelial cell line (data not shown). Similar to the re-
sults obtained in fibroblasts, we also found that prolonged
curcumin treatment (8 hours) led to a reduction of TGFb
receptor type II levels on mesangial cells (Fig. 8B). Thus,
the inhibitory effect of curcumin on TGFb signals can be
observed in multiple renal cell types.
Down-regulation of c-jun expression mimics curcumin
effects on TGF-b–induced gene expression
Curcumin acts as an inhibitor of the transcription factor
c-jun by directly inhibiting the binding of the c-jun/AP-
1 complex to its cognate DNA sequence. Because acti-
vation of c-jun/AP-1 by TGF-b has been shown to be
involved in TGF-b–induced fibronectin synthesis, we
wondered if the AP-1 inhibitory effect of curcumin might
be responsible for the inhibition of TGF-b effects after
short treatment periods.
To address this issue, we measured the effect of re-
duced levels of cellular c-jun, the main component of the
AP-1 complex, on TGF-b–regulated gene expression. To
reduce cellular c-jun protein, we used an RNA in-
terference (RNAi) technique. RNAi is induced in
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Fig. 8. Curcumin blocks TGFb effects in mesangial cells and reduces
TbRII expression. (A) Mesangial cells were incubated with curcumin
(10 lmol/L) for 30 minutes, followed by treatment with TGF-b for the
indicated period of time. mRNA expression was analyzed by Northern
blotting. The mean ± SD of values obtained from densitometric analy-
sis of all individual experiments are shown in (A). ∗P < 0.01 vs. TGF-b
alone. (B) Curcumin effects on baseline TGF-b receptor type II (TbRII)
expression were analyzed in mesangial cells incubated with curcumin at
the indicated dose for 8 hours. TbRII protein expression was analyzed
by Western blot along with b-actin as a loading control. The insert shows
results of a typical experiment, the graph shows the mean ± SD of val-
ues obtained from densitometric analysis of all individual experiments.
∗P < 0.01 vs. control.
mammalian cells by short interfering RNAs (siRNA),
which are double-stranded, 21-base pair RNA molecules
that are homologous to the targeted RNA, and induce
selective destruction of target RNA through a multi-
enzyme complex (for a recent review, see [11]). As Fig-
ure 9 shows, transfection of a siRNA molecule that tar-
gets c-jun reduces cellular c-jun levels by about 70% after
a treatment period of 48 hours. Treatment of cells with
single stranded components of the siRNA complex, ei-
ther high-dose sense (seRNA) or same-dose antisense
(asRNA) does not affect c-jun protein (Fig. 9).
As Figure 10 shows, c-jun–depleted renal fibroblasts
produce slightly less TGF-b , FN, and COL I at base-
line, and show a significantly reduced response to treat-
ment with TGF-b . Interestingly, c-jun depletion slightly
increases PAI-1 mRNA levels both in the absence of
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Fig. 9. Targeting c-jun with RNA interference reduces cellular c-jun
levels. Fibroblasts were treated for 48 hours with a siRNA molecule that
targets bp 445 to 466 of c-jun mRNA. Total c-jun expression was mea-
sured by Western blot (A) and standardized for densitometric analysis
to b-actin levels (B). ∗P < 0.01 vs. control.
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Fig. 10. c-jun siRNA reduces TGF-b–induced expression of FN, TGF-
b, and COL I. Fibroblasts were treated with c-jun siRNA (2.5 nmol/L)
for 48 hours, followed by treatment with TGF-b for 6 hours. mRNA
expression was analyzed by Northern blotting (A). The mean ± SD
of values obtained from densitometric analysis of all individual experi-
ments is shown (B). ∗P < 0.01 vs. TGF-b alone.
added TGF-b (second bar of Fig. 11), and when TGF-
b is present (third and fourth bars, Fig. 11). These effects
are also seen when TGF-b–induced protein expression
is analyzed (Fig. 12). Baseline and TGF-b–induced PAI-
1 protein in cell culture supernatant is increased after
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Fig. 11. c-jun depletion increases PAI-1 mRNA and protein expres-
sion. Samples shown in Figure 9 were analyzed for PAI-1 expression by
Northern blotting (A). The mean ± SD of values obtained from densit-
ometric analysis of all individual experiments is shown (B). ∗P < 0.01
vs. TGF-b alone.
c-jun depletion, and the TGF-b–induced increase in fi-
bronectin levels is reduced to baseline. These data show
that curcumin effects on TGF-b–induced gene transcrip-
tion are mimicked to a great degree by inhibition of
c-jun/AP-1.
DISCUSSION
In this study, we analyzed the antifibrotic properties of
curcumin in renal cells. The main finding of our study is
that curcumin blocks TGF-b–induced expression of sev-
eral mediators of fibrosis. Furthermore, this antifibrotic
effect of curcumin is mediated through down-regulation
of TbRII expression, and probably through inhibition of
the transcription factor c-jun/AP-1.
Curcumin is a naturally occurring polyphenolic com-
pound derived from the root of Curcuma longa, and
is consumed in high quantities in India, where it is
used as a spice and as an anti-inflammatory compound
in traditional medicine. Increasingly, its therapeutic ef-
fects are being investigated in well-defined models of
disease, such as inflammatory hepatic and pancreatic
disease [12–14] and pulmonary models of inflammation-
triggered fibrosis [4, 15]. The antifibrotic effect of cur-
cumin was first demonstrated in the bleomycin model
of pulmonary fibrosis, where curcumin application pre-
vented collagen accumulation [4]. No mechanistic expla-
nation was proposed in that study. Here, we show that
curcumin blocks the action of TGF-b , which drives fi-
brosis in the bleomycin model, and is the predominant
fibrotic cytokine in renal disease.
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Fig. 12. c-jun siRNA effects on TGF-b–induced protein synthesis. Fi-
broblasts were treated with c-jun siRNA (2.5 nmol/L) for 48 hours,
followed by treatment with TGF-b for 24 hours. PAI-1 protein released
into the cell culture supernatant was analyzed by Western blot. (A) Re-
sults of a typical experiment. The mean ± SD of values obtained from
densitometric analysis of all individual experiments is shown (B). FN
protein in the supernatant was measured by ELISA (C). ∗P < 0.01 vs.
TGF-b alone.
Limiting TGF-b effects has been shown to be bene-
ficial in a number of fibrotic renal disease models, and
there is good preliminary data supporting this concept
in human fibrotic diseases. TGF-b over-expression has
been linked to angiotensin II [16], and as large clini-
cal trials have shown, anti-angiotensin therapy slows the
progression of renal disease in humans. However, clini-
cal progression to end-stage renal disease (ESRD) is not
halted, and experimental studies show that even maxi-
mal angiotensin blockade with ACEi or ARBs, or the
combination of both, fails to normalize TGF-b levels in
experimental fibrotic renal disease [9]. Therefore, ther-
apies that directly target TGF-b or components of the
TGF-b signal transduction cascade are of great inter-
est. As our data show, curcumin inhibits the TGF-b–
induced increase of several genes and proteins that either
contribute directly (collagen I, fibronectin) or indirectly
(TGF-b1, PAI-1) to the accumulation of matrix proteins
in renal disease. The inhibitory effect of curcumin was
quite profound because TGF-b effects were almost com-
pletely blocked for an extended time even when curcumin
was given after TGF-b stimulation was initiated. While
this manuscript was prepared, an inhibitory effect of
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curcumin on TGFb expression was reported in the model
of amiodaron-induced lung fibrosis, in which curcumin
reduced TGFb expression and subsequent fibrosis [17].
In an attempt to elucidate mechanisms underlying the
inhibitory effect of curcumin, we analyzed key compo-
nents of TGF-b signal transduction. TGF-b signaling is
initiated by TGF-b binding to its cell membrane receptor
and formation of the activated receptor complex, which
then phosphorylates intracellular messenger molecules
like SMAD proteins [2]. Our data show that curcumin
decreased TGF-b receptor II protein levels. This was as-
sociated with reduced SMAD2/3 phosphorylation after
curcumin treatment, indicating reduced biological activ-
ity of the activated TGF-b receptor complex. The effect
of curcumin on TbRII expression was quite specific; no
down-regulation of either TbRI, which has high homol-
ogy to TbRII, or the unrelated angiotensin receptor type
I was observed. Because curcumin inhibits the activity of
the transcription factor c-jun [5–8], and also has nuclear
factor kB (NF-jB) inhibitory activity [12, 18–21], it is pos-
sible that curcumin limits essential transcription factor
availability, which subsequently leads to reduced TbRII
mRNA expression. AP-1 sites have been reported in hu-
man, canine, and mouse TbRII promoters. AP-1 activity
correlates with inducible TbRII promoter activity in re-
nal epithelial cells stimulated with high glucose of ANG
II [15, 22]. Whether AP-1 is also involved in maintaining
unstimulated, constitutive TbRII expression, which was
analyzed in this study, is presently unclear and demands
further investigation.
Reducing endogenous TbRII activity indirectly by
over-expressing soluble TbRII has been shown to block
TGF-b action and fibrosis in fibrotic kidney disease in
vivo [23]. Thus, down-regulation of TbRII by curcumin
provides an attractive explanation for the antifibrotic cur-
cumin effects observed in vivo in the bleomycin model.
The effects of curcumin we observed in vitro, however,
suggest that curcumin acts in at least two ways. Dose and
time experiments showed that high doses of curcumin
(5 to 10 lmol/L) and prolonged incubation times (at
least 6 hours) were necessary to induce down-regulation
of TbRII. Thus, while decreased TbRII may explain
the observed reduction in TGF-b–induced proteins with
curcumin and TGF-b treatment for 24 hours (Fig. 4),
decreased TbRII cannot explain the observed action of
curcumin to markedly reduced TGF-b effects with only a
30-minute curcumin treatment (Figs. 1 to 3). We therefore
investigated whether the inhibitory effect of curcumin
on c-jun activity might explain these early effects. TGF-
b induces c-jun transcriptional activity [24], and induc-
tion of fibronectin expression has been directly linked
to c-jun transcriptional activity [25]. Our data show that
down-regulation of c-jun protein by RNA interference
was associated with reduced induction of FN, TGF-b ,
and COLI mRNA and FN protein after TGF-b treat-
ment. Although indirect, these data suggest that c-jun
may regulate TGF-b–induced genes. Consistent with this
idea are data published by Hocevar et al [25], show-
ing that TGF-b–induced fibronectin production, but not
PAI-1 production, is dependent on c-jun signaling. Us-
ing dominant negative mutants of c-jun terminal kinase
(JNK), which phosphorylates and activates c-jun, and of
upstream activators of JNK, they were able to show that
TGF-b induces FN synthesis almost exclusively through
a c-jun–dependent pathway, with little or no contribu-
tion of the classic SMAD pathway. Our data suggest that
regulation of TGF-b target genes, COLI and TGF-b , in
addition to FN, may also be dependent on c-jun activity.
While c-jun depletion decreased expression of TGF-b ,
FN, and COLI, c-jun depletion increased PAI-1 mRNA
and protein (Fig. 12), suggesting that c-jun negatively reg-
ulates PAI-1 expression in NRK49F cells. This conclu-
sion is consistent with findings published by Verrecchia
et al, who analyzed the interaction of c-jun with SMAD
proteins in TGF-b signaling [26–28]. Using an artificial
promoter-reporter construct derived from the PAI-1 pro-
moter, they showed that in both unstimulated cells and
TGF-b–stimulated cells, c-jun physically interacts with
SMAD proteins, blocking their DNA-binding ability and
thereby limiting basal and TGF-b–induced stimulation
of the PAI-1 promoter. These data offer a mechanistic
explanation for the effects of c-jun depletion on PAI-1
expression seen in our experiments. However, they fail
to explain the inhibitory effect of curcumin on PAI-1 in-
duction after TGF-b treatment seen in our study (Figs. 1
and 2).
The implications of our study are several. First, we have
demonstrated that curcumin is a potent blocker of TGF-b
effects in renal cells. Given the proven ability of curcumin
to block the accumulation of extracellular matrix proteins
in a pulmonary fibrosis model, and the known pivotal role
of TGF-b in renal fibrosis, it is reasonable to assume that
curcumin will be beneficial in chronic renal disease. Sec-
ond, we have been able to show that the antifibrotic effect
of curcumin in vitro is mediated by at least 2 mechanisms,
down-regulation of TbRII and inhibition of c-jun activity.
Third, we have successfully used RNA interference tech-
nology to study signaling pathways in renal cells. Given
the growing concern over the specificity of small molecule
inhibitors of signaling molecules, shutting down signaling
pathways with RNAi at precisely targeted sites offers an
attractive and valid technical approach.
One possible caveat of our study is the direct applica-
bility of the doses used in our study to the situation in
vivo. Curcumin is highly lipohilic, cannot be injected in-
travenously in long-term experiments, and has a poor oral
bioavailability [29–31]. Although doses of up to 8 g per
day have been reported to be both safe and efficacious in
humans [32], it is unclear if oral dosing will provide the
drug levels necessary to achieve the effects demonstrated
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in this study. The recent development of water-soluble
curcumin analogs [33, 34], which could presumably be
injected intravenously, might aid in the further in vivo
testing of this compound.
CONCLUSION
Curcumin is a novel antifibrotic substance that reduces
TGF-b effects and might be a potential add-on therapeu-
tic to the standard anti-angiotensin therapies currently
used in the treatment of chronic renal disease.
Reprint requests to Nancy A. Noble, Fibrosis Research Laboratory,
391 Chipeta Way, Suite E, Salt Lake City, UT 84108.
E-mail: Nancy.Noble@hsc.utah.edu
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